PL4233850T3 - Postacie użytkowe będące kapsułkami - Google Patents

Postacie użytkowe będące kapsułkami

Info

Publication number
PL4233850T3
PL4233850T3 PL23160271.5T PL23160271T PL4233850T3 PL 4233850 T3 PL4233850 T3 PL 4233850T3 PL 23160271 T PL23160271 T PL 23160271T PL 4233850 T3 PL4233850 T3 PL 4233850T3
Authority
PL
Poland
Prior art keywords
capsule formulations
capsule
formulations
Prior art date
Application number
PL23160271.5T
Other languages
English (en)
Inventor
Manmohan Reddy Leleti
Jay P Powers
Original Assignee
Chemocentryx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70849818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4233850(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemocentryx, Inc. filed Critical Chemocentryx, Inc.
Publication of PL4233850T3 publication Critical patent/PL4233850T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL23160271.5T 2018-11-30 2019-11-27 Postacie użytkowe będące kapsułkami PL4233850T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862773848P 2018-11-30 2018-11-30

Publications (1)

Publication Number Publication Date
PL4233850T3 true PL4233850T3 (pl) 2025-03-17

Family

ID=70849818

Family Applications (2)

Application Number Title Priority Date Filing Date
PL23160271.5T PL4233850T3 (pl) 2018-11-30 2019-11-27 Postacie użytkowe będące kapsułkami
PL19889873.6T PL3886820T3 (pl) 2018-11-30 2019-11-27 Postacie użytkowe będące kapsułkami

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19889873.6T PL3886820T3 (pl) 2018-11-30 2019-11-27 Postacie użytkowe będące kapsułkami

Country Status (31)

Country Link
US (4) US20200170957A1 (pl)
EP (3) EP3886820B8 (pl)
JP (1) JP7342124B2 (pl)
KR (1) KR102586747B1 (pl)
CN (1) CN113164403A (pl)
AR (1) AR117219A1 (pl)
AU (1) AU2019389031B2 (pl)
BR (1) BR112021010285A2 (pl)
CA (1) CA3120999C (pl)
CL (1) CL2021001389A1 (pl)
CY (1) CY1126079T1 (pl)
DK (2) DK4233850T3 (pl)
ES (2) ES2943492T3 (pl)
FI (2) FI3886820T3 (pl)
HR (2) HRP20241735T1 (pl)
HU (2) HUE069633T2 (pl)
IL (1) IL283450B2 (pl)
LT (2) LT4233850T (pl)
MA (2) MA54318B1 (pl)
MD (2) MD3886820T2 (pl)
MX (1) MX2021006242A (pl)
NZ (1) NZ776554A (pl)
PL (2) PL4233850T3 (pl)
PT (2) PT4233850T (pl)
RS (2) RS66362B1 (pl)
SG (1) SG11202105572UA (pl)
SI (2) SI4233850T1 (pl)
SM (2) SMT202400521T1 (pl)
TW (1) TWI827745B (pl)
WO (1) WO2020112961A1 (pl)
ZA (1) ZA202103820B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164403A (zh) 2018-11-30 2021-07-23 凯莫森特里克斯股份有限公司 胶囊制剂
KR20220098754A (ko) 2019-11-08 2022-07-12 케모센트릭스, 인크. 보체 성분 C5a 수용체의 비정질 형태
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
CA3192880A1 (en) * 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
CN116635075A (zh) * 2020-12-21 2023-08-22 坎莫森特里克斯公司 使用c5a抑制剂治疗c3肾小球病
JP2025516701A (ja) * 2022-05-19 2025-05-30 ダウ グローバル テクノロジーズ エルエルシー Ｂｃｓクラスｉｉの薬物の改良された可溶化のためのｐｅｇベースのインターポリマー錯体の使用
US20250164505A1 (en) * 2023-11-20 2025-05-22 Qatar Foundation For Education, Science And Community Development Detection of extracellular vesicle biomarkers for the diagnosis of autism spectrum disorder
WO2025203055A1 (en) * 2024-03-26 2025-10-02 Council Of Scientific And Industrial Research Encapsulated dihydrofolate formulation for dietary supplementation as effective nutraceutical supplement and method of preparation thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038681A1 (es) 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
AU2005309808A1 (en) * 2004-11-24 2006-06-01 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
MX363066B (es) * 2007-05-29 2019-03-07 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.
JP5819730B2 (ja) 2008-12-22 2015-11-24 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
US20110312973A1 (en) 2010-03-10 2011-12-22 Bernd Liepold Solid compositions
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
EP2659090B1 (en) 2010-12-27 2017-08-23 Seven Generations Energy Ltd. Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources
CN106102716A (zh) 2014-02-05 2016-11-09 斯洛文尼亚莱柯制药股份有限公司 雄激素受体拮抗剂的固体药物组合物
JP6898229B6 (ja) 2014-09-29 2021-07-28 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト製造における方法及び中間体
SG11201805828YA (en) 2016-01-14 2018-08-30 Chemocentryx Inc Method of treating c3 glomerulopathy
SG11201808625QA (en) 2016-04-04 2018-10-30 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS
DK3411400T3 (da) 2017-04-03 2021-10-11 Inflarx Gmbh Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet
CN111741754A (zh) 2017-10-30 2020-10-02 凯莫森特里克斯股份有限公司 作为免疫调节剂的氘代化合物
KR20200109297A (ko) 2017-10-31 2020-09-22 케모센트릭스, 인크. 소변 sCD163의 C5aR 억제제 감소
JP2021527062A (ja) 2018-06-07 2021-10-11 ケモセントリックス，インコーポレイティド ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果
CN113164403A (zh) 2018-11-30 2021-07-23 凯莫森特里克斯股份有限公司 胶囊制剂

Also Published As

Publication number Publication date
EP4233850A3 (en) 2023-09-20
HUE062551T2 (hu) 2023-11-28
BR112021010285A2 (pt) 2021-08-17
MA62992B1 (fr) 2025-01-31
DK3886820T3 (da) 2023-05-15
IL283450A (en) 2021-07-29
LT4233850T (lt) 2025-01-27
PL3886820T3 (pl) 2023-08-14
FI4233850T3 (fi) 2024-12-30
JP2022510304A (ja) 2022-01-26
SI4233850T1 (sl) 2025-03-31
CL2021001389A1 (es) 2021-12-24
LT3886820T (lt) 2023-06-12
US20240299306A1 (en) 2024-09-12
MX2021006242A (es) 2021-09-10
EP3886820B8 (en) 2023-05-17
RS66362B1 (sr) 2025-01-31
FI3886820T3 (fi) 2023-05-25
HRP20241735T1 (hr) 2025-02-28
ZA202103820B (en) 2026-03-25
EP3886820A1 (en) 2021-10-06
AU2019389031B2 (en) 2023-06-15
EP4233850B1 (en) 2024-10-02
AU2019389031A1 (en) 2021-06-17
ES2998858T3 (en) 2025-02-21
PT4233850T (pt) 2024-12-30
NZ776554A (en) 2024-12-20
SI3886820T1 (sl) 2023-07-31
KR102586747B1 (ko) 2023-10-06
DK4233850T3 (da) 2025-01-02
HUE069633T2 (hu) 2025-04-28
EP4487915A2 (en) 2025-01-08
CA3120999C (en) 2025-04-01
ES2943492T3 (es) 2023-06-13
WO2020112961A1 (en) 2020-06-04
CN113164403A (zh) 2021-07-23
EP4487915A3 (en) 2025-03-19
US20220233453A1 (en) 2022-07-28
SMT202300153T1 (it) 2023-09-06
IL283450B2 (en) 2024-06-01
MD4233850T2 (ro) 2025-02-28
TWI827745B (zh) 2024-01-01
CY1126079T1 (el) 2023-11-15
AR117219A1 (es) 2021-07-21
PT3886820T (pt) 2023-05-24
JP7342124B2 (ja) 2023-09-11
KR20210098489A (ko) 2021-08-10
SMT202400521T1 (it) 2025-01-14
US11951214B2 (en) 2024-04-09
HRP20230551T1 (hr) 2023-08-18
SG11202105572UA (en) 2021-06-29
US20250375385A1 (en) 2025-12-11
MD3886820T2 (ro) 2023-07-31
EP4233850A2 (en) 2023-08-30
EP3886820B1 (en) 2023-04-12
IL283450B1 (en) 2024-02-01
TW202038952A (zh) 2020-11-01
EP3886820A4 (en) 2022-08-24
MA54318B1 (fr) 2023-08-31
MA54318A (fr) 2021-10-06
RS64250B1 (sr) 2023-06-30
CA3120999A1 (en) 2020-06-04
US20200170957A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
IL273541A (en) formulations
IL273282A (en) Niraprib formulations
IL269630A (en) Niraprib formulations
IL269621A (en) Niraparib formulations
IL283450A (en) capsule formulations
GB201809976D0 (en) Novel formulations
GB201707189D0 (en) Novel formulations
ZA202006570B (en) Pharmaceutical formulations
GB201707188D0 (en) Novel formulations
GB201707187D0 (en) Novel formulations
SG11202010792TA (en) Improved pharmaceutical formulations
IL271908A (en) Over-compressed pharmaceutical preparations
SG11202011823SA (en) Activator-nucleator formulations
ZAA201801557S (en) Capsule
ZAA201801556S (en) Capsule
PH32018000897S1 (en) Capsule
GB201819028D0 (en) Butanol-based formulations
IL268195A (en) Solid fosmetpantothenate formulations
ZAF201800730S (en) Capsule
GB201806710D0 (en) Capsule
GB201808386D0 (en) Formulations
GB201804545D0 (en) Formulations
GB201803201D0 (en) Formulations
GB201714461D0 (en) Formulations
GB201716291D0 (en) Novel formulations